Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02124902 · ClinicalTrials.gov registry record · Phase 2
Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti-tumor Activity
A Phase 2 study, sponsored by Washington University School of Medicine.
- Terminated
- Registry status
- Phase 2
- Development phase
- 148
- Enrollment target
NCT02124902 is a Phase 2 study that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 148 participants.
The verdict
NCT02124902, a Phase 2 study, was terminated before completion, sponsored by Washington University School of Medicine.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 148 participants
- Enrollment target
Study Summary
This is a single arm open label phase II study in women with clinical stage 2 or 3 triple negative breast cancer to assess the anti-tumor activity (in terms of pathologic complete response rate) of neoadjuvant docetaxel in combination with carboplatin. Patient derived xenografts will also be developed simultaneously for the purposes of genoproteomic analysis. Please note that Baylor College of Medicine (BCM) has a parallel study the same as this study. Baylor is expected to enroll approximately 19 participants that have complied with the inclusion and exclusion criteria for this study (excluded participants from BCM will include male participants or participants with inflammatory breast cancer). The investigators will pool participants and data from the BCM study and the study at Washington University School of Medicine. Pooling the data will potentially improve statistical power.
Interventions
- DRUG Carboplatin
- DRUG Docetaxel
- PROCEDURE FDG-PET/MR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 148 participants |
| Start Date | 2014-07-07 |
| Est. Completion | 2021-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02124902
The ClinicalTrials.gov registry entry for NCT02124902 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 148 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Carboplatin is the first listed.
NCT02124902 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02124902 about?
NCT02124902 is a clinical study titled "Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti-tumor Activity". This is a single arm open label phase II study in women with clinical stage 2 or 3 triple negative breast cancer to assess the anti-tumor activity (in terms of pathologic complete response rate) of neoadjuvant docetaxel in combination with carboplatin. Patient derived xenografts will also be develop...
What is the current status of trial NCT02124902?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 148 participants. The study started on 2014-07-07. Estimated completion is 2021-12-31.
What interventions are being tested in trial NCT02124902?
The interventions under investigation include: Carboplatin (DRUG), Docetaxel (DRUG), FDG-PET/MR (PROCEDURE).
Who is sponsoring clinical trial NCT02124902?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.